(Q39449289)

English

Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

object named as

Rory Wolfe

4

0 references

Collaborative Study Group

8

object named as

Collaborative Study Group

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Sara E Ivory

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

David K Packham

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Anne T Reutens

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Richard D Rohde

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Julia Lewis

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Robert C Atkins

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

516-524

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Diabetes: Diabetic kidney disease: act now or pay later

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Proteinuria in diabetic kidney disease: a mechanistic viewpoint

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Association between albuminuria and proteinuria in the general population: the AusDiab Study.

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Relation between kidney function, proteinuria, and adverse outcomes

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Kidney function and risk triage in adults: threshold values and hierarchical importance

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

The pathogenesis of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Comparison of different measures of urinary protein excretion for prediction of renal events

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Nonalbuminuric renal insufficiency in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

A new equation to estimate glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Renoprotective effects of renin-angiotensin-system inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1111%2FNEP.12053

21 January 2018

Identifiers

10.1111/NEP.12053

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39449289&oldid=1828785226"